MT Petrucci

492 total citations
15 papers, 299 citations indexed

About

MT Petrucci is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, MT Petrucci has authored 15 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 8 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in MT Petrucci's work include Multiple Myeloma Research and Treatments (14 papers), Cancer Treatment and Pharmacology (4 papers) and Glycosylation and Glycoproteins Research (2 papers). MT Petrucci is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Cancer Treatment and Pharmacology (4 papers) and Glycosylation and Glycoproteins Research (2 papers). MT Petrucci collaborates with scholars based in Italy, United States and United Kingdom. MT Petrucci's co-authors include Ryan J. A. Chang, J Woodliff, Hironobu Hata, Hong Xiao, Joshua Epstein, Meletios Α. Dimopoulos, Martin Kropff, Roman Hájek, Mario Boccadoro and Michel Delforge and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Treatment Reviews.

In The Last Decade

MT Petrucci

13 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
MT Petrucci Italy 8 240 165 153 47 34 15 299
Johannes M. Waldschmidt Germany 9 207 0.9× 149 0.9× 158 1.0× 45 1.0× 36 1.1× 53 310
Hamdi Sati United Kingdom 5 160 0.7× 74 0.4× 138 0.9× 32 0.7× 12 0.4× 9 229
María-Ángeles Montalbán Spain 5 276 1.1× 217 1.3× 178 1.2× 40 0.9× 69 2.0× 5 350
Vincent Nadeem Canada 4 106 0.4× 133 0.8× 104 0.7× 40 0.9× 16 0.5× 5 227
Scott VanWier United States 4 209 0.9× 167 1.0× 72 0.5× 30 0.6× 49 1.4× 4 275
Joan Bladé Spain 6 416 1.7× 316 1.9× 238 1.6× 46 1.0× 100 2.9× 12 490
Ellen Ingalla United States 5 127 0.5× 241 1.5× 126 0.8× 32 0.7× 69 2.0× 12 339
Manuela Gambella Italy 8 193 0.8× 181 1.1× 116 0.8× 61 1.3× 24 0.7× 13 283
Shayu Deshpande United States 9 117 0.5× 113 0.7× 59 0.4× 48 1.0× 20 0.6× 17 215
Lieve Adriaens United States 7 73 0.3× 184 1.1× 164 1.1× 57 1.2× 12 0.4× 14 306

Countries citing papers authored by MT Petrucci

Since Specialization
Citations

This map shows the geographic impact of MT Petrucci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MT Petrucci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MT Petrucci more than expected).

Fields of papers citing papers by MT Petrucci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MT Petrucci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MT Petrucci. The network helps show where MT Petrucci may publish in the future.

Co-authorship network of co-authors of MT Petrucci

This figure shows the co-authorship network connecting the top 25 collaborators of MT Petrucci. A scholar is included among the top collaborators of MT Petrucci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with MT Petrucci. MT Petrucci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Vozella, Federico, Maria Teresa Rizzo, Tommaso Zà, et al.. (2021). Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. Annals of Hematology. 100(4). 1059–1063. 7 indexed citations
3.
Cook, Gary, Alessandro Corso, Matthew Streetly, et al.. (2019). PS1425 RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. HemaSphere. 3(S1). 656–656. 2 indexed citations
4.
5.
Palumbo, Antonio, M. Delforge, J. Catalano, et al.. (2011). Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older.. Journal of Clinical Oncology. 29(15_suppl). 8007–8007. 22 indexed citations
6.
Richardson, PG, Rudolf Schlag, Nuriet K. Khuageva, et al.. (2009). A220 Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone. Clinical Lymphoma & Myeloma. 9. S36–S37. 1 indexed citations
7.
Kropff, Martin, PG Richardson, Rudolf Schlag, et al.. (2009). A084 Similar Benefit in Patients Aged q 75 Years Versus < 75 Years with VMP in First-Line MM and Bortezomib in Relapsed MM. Clinical Lymphoma & Myeloma. 9. S12–S12. 2 indexed citations
8.
Palumbo, Antonio, Rudolf Schlag, Nuriet K. Khuageva, et al.. (2008). Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm). 93. 83–83. 7 indexed citations
9.
Rawstron, Andy C., Alberto Órfão, Gema Mateo, et al.. (2007). Report of the European Myeloma Network (EMN) workshop on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica.
10.
Palumbo, Antonio, Letizia Canepa, Stefano D’Ardìa, et al.. (2006). Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. Journal of Clinical Oncology. 24(18_suppl). 7518–7518. 15 indexed citations
11.
Palumbo, Antonio, S Triolo, Luca Baldini, et al.. (2000). Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.. PubMed. 85(5). 508–13. 14 indexed citations
12.
Lemoli, Roberto M., Alessandra Fortuna, Agostino Tafuri, et al.. (1996). Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. Blood. 87(9). 3852–3859. 27 indexed citations
13.
Hata, Hironobu, Hong Xiao, MT Petrucci, et al.. (1993). Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood. 81(12). 3357–3364. 6 indexed citations
14.
Hata, Hironobu, Hong Xiao, MT Petrucci, et al.. (1993). Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood. 81(12). 3357–3364. 120 indexed citations
15.
Mandelli, Franco, M Tribalto, Giuseppe Avvisati, et al.. (1988). Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. Cancer Treatment Reviews. 15. 43–48. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johannes M. Waldschmidt Breakdown of academic impact, for papers by Hamdi Sati Breakdown of academic impact, for papers by María-Ángeles Montalbán Breakdown of academic impact, for papers by Vincent Nadeem Breakdown of academic impact, for papers by Scott VanWier Breakdown of academic impact, for papers by Joan Bladé Breakdown of academic impact, for papers by Ellen Ingalla Breakdown of academic impact, for papers by Manuela Gambella Breakdown of academic impact, for papers by Shayu Deshpande Breakdown of academic impact, for papers by Lieve Adriaens
Rankless by CCL
2026